Consequently, cetuximab is a powerful stimulus of NK cell-mediated ADCC via activation of FcγRIIIa against cetuximab-coated tumor cells and for induction of cytokine release, especially IFN-γ and TNFα secretion. This evidence concerns the gene FCGR3A and neoplasm.